News

Bicycle Therapeutics has obtained a global license from Pepscan to utilize its proprietary constrained peptide chemistry technology. The parties propose to closely collaborate on the development of structurally modified peptides that will act as a novel class of therapeutic molecules.

Pepscan‟s proprietary technology allows the creation of constrained peptides covalently linked to an organochemical scaffold. Bicycle Therapeutics applies powerful biological selection techniques in combination with the Pepscan technology to identify and optimize chemically constrained cyclic peptides with high target specificity and binding affinities. These peptides could be regarded as mini-antibodies with covalent organic cores that are also stable to unfolding and to the action of proteases. As such they should overcome the weaknesses of previous generations of peptide based therapeutics and combine the best features of biological and small molecular weight drugs.